UBS Group
GYRE icon

UBS Group’s Gyre Therapeutics GYRE Stock Holding History

UBS Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-28
Closed -$59K – 9013
2014
Q4 		$59K Buy
+28
New +$53.9K ﹤0.01% 6276

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group's GYRE Position: Q1 2026 in Review

UBS Group increased its Gyre Therapeutics (GYRE) stake by 120% in Q1 2026, buying an estimated $89.3K and bringing the position to 21,087 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #6800.

UBS Group first reported a position in GYRE in Q4 2015 and has held it in 36 quarters since. The position peaked at $1.12M in Q4 2015. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • UBS Group held 21,087 shares of Gyre Therapeutics worth $147K as of Q1 2026.
  • UBS Group bought 11,503 Gyre Therapeutics shares in Q1 2026, an estimated $89.3K.
  • Gyre Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6800 holding.
  • UBS Group first reported a position in Gyre Therapeutics in Q4 2015 and has held it in 36 quarters since.
  • UBS Group's Gyre Therapeutics position peaked at $1.12M in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.